Koshinski Asset Management’s Novartis NVS Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$365K Buy
2,330
+15
+0.6% +$2.25K 0.02% 544
2026
Q1
$354K Buy
2,315
+220
+11% +$33.7K 0.02% 529
2025
Q4
$289K Buy
2,095
+25
+1% +$3.27K 0.02% 573
2025
Q3
$265K Buy
2,070
+104
+5% +$12.7K 0.02% 608
2025
Q2
$238K Sell
1,966
-171
-8% -$19.3K 0.02% 598
2025
Q1
$238K Hold
2,137
0.02% 553
2024
Q4
$208M Buy
2,137
+131
+7% +$14K 0.02% 595
2024
Q3
$231K Sell
2,006
-109
-5% -$12.4K 0.02% 556
2024
Q2
$229K Buy
2,115
+35
+2% +$3.51K 0.02% 535
2024
Q1
$201K Sell
2,080
-452
-18% -$46.3K 0.02% 547
2023
Q4
$256K Buy
2,532
+435
+21% +$42K 0.04% 428
2023
Q3
$214K Hold
2,097
0.02% 512
2023
Q2
$212K Sell
2,097
-738
-26% -$73.8K 0.02% 549
2023
Q1
$261K Sell
2,835
-169
-6% -$14.8K 0.03% 456
2022
Q4
$273K Buy
3,004
+33
+1% +$2.78K 0.03% 483
2022
Q3
$226K Sell
2,971
-744
-20% -$61.7K 0.03% 473
2022
Q2
$314K Sell
3,715
-404
-10% -$35.4K 0.03% 455
2022
Q1
$361K Buy
4,119
+85
+2% +$7.36K 0.03% 449
2021
Q4
$353K Buy
4,034
+40
+1% +$3.32K 0.03% 479
2021
Q3
$327K Buy
3,994
+1,182
+42% +$106K 0.03% 486
2021
Q2
$257K Sell
2,812
-1,006
-26% -$89.6K 0.03% 480
2021
Q1
$326K Buy
3,818
+582
+18% +$52.2K 0.03% 456
2020
Q4
$306K Sell
3,236
-58
-2% -$5.07K 0.04% 430
2020
Q3
$291 Buy
3,294
+10
+0.3% +$866 0.04% 397
2020
Q2
$287K Buy
3,284
+48
+1% +$4.14K 0.05% 396
2020
Q1
$267K Buy
3,236
+140
+5% +$12.5K 0.06% 364
2019
Q4
$293K Buy
+3,096
New +$278K 0.05% 408
2019
Q2
Sell
-3,186
Closed -$274 344
2019
Q1
$274 Sell
3,186
-800
-20% -$64.2K 0.07% 304
2018
Q4
$307K Sell
3,986
-1,470
-27% -$114K 0.08% 295
2018
Q3
$421K Buy
+5,456
New +$403K 0.06% 361
2018
Q1
Sell
-2,798
Closed -$210K 404
2017
Q4
$210K Buy
+2,798
New +$211K 0.05% 404

Other funds holding NVS

Koshinski Asset Management's NVS Position: Q2 2026 in Review

Koshinski Asset Management increased its Novartis (NVS) stake by 0.65% in Q2 2026, buying an estimated $2.25K and bringing the position to 2,330 shares worth $365K. The position accounts for 0.02% of the portfolio, ranked #544.

Koshinski Asset Management first reported a position in NVS in Q4 2017 and has held it in 31 quarters since. The position peaked at $208M in Q4 2024. 1,614 funds tracked by Wall St. Rank hold NVS as of Q2 2026.

  • Koshinski Asset Management held 2,330 shares of Novartis worth $365K as of Q2 2026.
  • Koshinski Asset Management bought 15 Novartis shares in Q2 2026, an estimated $2.25K.
  • Novartis made up 0.02% of Koshinski Asset Management's portfolio in Q2 2026, its #544 holding.
  • Koshinski Asset Management first reported a position in Novartis in Q4 2017 and has held it in 31 quarters since.
  • Koshinski Asset Management's Novartis position peaked at $208M in Q4 2024.
  • 1,614 funds tracked by Wall St. Rank held Novartis as of Q2 2026.

Based on Koshinski Asset Management's 13F filing for Q2 2026, filed 27 Jul 2026.